Kyle Rasbach, PhD, PharmD


Kyle joined Pappas Capital in 2018, bringing with him extensive experience in clinical pharmacology, basic science and healthcare equity research. Prior to joining Pappas, he was an equity research analyst and Vice President at T. Rowe Price in Baltimore, where he managed pharmaceutical, specialty pharmaceutical and biotechnology investments for all T. Rowe Price funds. During his time at T. Rowe, Kyle led the firm’s IPO investment in Pappas portfolio company CoLucid Pharmaceuticals (NASDAQ: CLCD), which was eventually sold to Eli Lilly for just under $1 billion. Prior to joining T. Rowe, Kyle was an equity research associate and Vice President at Cowen and Company in Boston, where he covered global pharmaceutical equities. He completed his postdoctoral work in the laboratory of Bruce Spiegelman at Harvard Medical School, where he contributed to a number of high profile publications, including papers in Cell, Cell Metabolism, Nature and PNAS. Kyle currently serves as a director for Balance Therapeutics, and as an observer for Mirum Pharmaceuticals and Ribometrix. He also serves on the board of directors of the NC Biosciences Organization (NCBIO).


Medical University of South Carolina (PhD in Pharmaceutical and Biomedical Sciences)
Medical University of South Carolina (Doctor of Pharmacy/PharmD)
The Citadel (MBA)

“There is nothing more invigorating than partnering with entrepreneurs who are committed to using science to make the world a healthier place.”

Serves as a Director for:

Serves as an Observer for:


  • Board Member, NC Biosciences Organization (NCBIO)